Clinical Trials Details

A Randomized, Open-Label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05) (Gilead Sciences GS-US-595-6184)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.

Learn More

Principal Investigator(s)

Jamie Stratton, MD


Mary Miller, LPN at 203-358-8879 or [email protected]


Bennett Cancer Center
One Hospital Plaza
Stamford, CT 06902
Main: 203-276-2695

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.